Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
The risk of pelvic floor disorders for women years after childbirth varied depending on mode of delivery, researchers found. Women with cesarean delivery had a lower hazard of stress urinary incontinence, overactive bladder, and pelvic organ prolapses compared with women with spontaneous vaginal deliveries, reported Joan L. Blomquist, MD, of Greater Baltimore Medical Center in Maryland, and colleagues. By contrast, women with operative vaginal delivery were associated with a higher hazard of anal incontinence and pelvic organ prolapse, they wrote in JAMA. Read more.
Source: MedPage Today, December 18, 2018
Medtronic won FDA approval to introduce the InterStim smart programmer to control the company’s InterStim neurostimulation system used to manage overactive bladder, bowel incontinence, and some types of urinary retention. The InterStim system delivers sacral neuromodulation therapy via an implant that looks similar to a cardiac pacemaker. Read more.
Medgadget, December 17, 2018
Specific locations of cerebral multiple sclerosis lesions appear to be associated with bowel incontinence, according to a study published online Dec. 11 in the Journal of Neuroimaging. Kilian Frohlich, M.D., from the University Hospital Erlangen in Germany, and colleagues used a voxel-wise lesion symptom mapping analysis to assess associations between bowel incontinence and cerebral multiple sclerosis lesions identified on magnetic resonance imaging of 51 patients. The researchers found associations between fecal incontinence in a total of 93 lesioned voxels, with 63 voxels located in the gray matter and 30 voxels in the white matter. Read more.
Source: Practice Update, December 17, 2018
Percutaneous tibial nerve stimulation (PTNS) improves overactive bladder (OAB) symptoms and decreases the number of nocturia episodes in patients who do not respond well to medication therapy, new study findings suggest. In a retrospective study of 183 female patients (mean age 74 years; 83% white) treated at a urogynecology center, 12 weeks of PTNS (30 minutes per week) reduced voiding frequency by 1 hour, nocturia episodes by 0.8, and urge incontinence by 10 episodes per week, Shilpa Iyer, MD, of the University of Chicago, and colleagues reported in International Urogynecology Journal. Previously, patients voided every 1.6 hours, awoke 2 to 3 times nightly to void, and averaged 3 urge incontinence episodes daily. Read more.
Source: Renal & Urology News, December 12, 2018
Nov. 25-30 acknowledges Nocturia Awareness Week, part of Bladder Health Month, which encourages people to take control of their urinary health. Nocturia, a treatable medical condition that forces you to wake up multiple times a night to urinate, affects nearly 50 million Americans and is a leading cause of sleep disruption.1, Nocturia can have mental and physical consequences, including: impaired memory3 and concentration, moodiness, depression, obesity, diabetes and a weakened immune system. However, most Americans have never heard of nocturia and think waking multiple times at night to urinate is normal. To help inform Americans so they do not unknowingly endure the consequences of nocturia, Avadel Pharmaceuticals, a leader in urological health and education, has brought together the most influential patient advocacy groups across specialty areas to form the Nocturia Council: American Alliance for Healthy Sleep, Caregiver Action Network, Healthy Women, Men’s Health Education Council, Men’s Health Network, Multiple Sclerosis Association of America, National Association for Continence, National Sleep Foundation, Simon Foundation for Continence and ZERO – The End of Prostate Cancer. Over the next few months, the Nocturia Council, with support from Avadel Pharmaceuticals, will kick off several educational initiatives to lessen the stigma of night-time urination and promote conversations with a healthcare professional about managing nocturia. Read more.
Source: Globe Newswire: November 29, 2018
Astellas has made another deal in the gene therapy category, licensing a candidate for treating faecal incontinence from US biotech Juventas Therapeutics. Terms of the deal haven’t been disclosed, but Astellas says it has taken an exclusive option on the non-viral gene therapy – called JVS-100 and in early-stage clinical development – in all world markets except China. It’s paying an upfront fee and will also fund preclinical and clinical studies of the therapy. JVS-100 is Ohio-based Juventas’ lead product candidate and delivers the gene sequence for stromal cell-derived factor-1 (SDF-1), a naturally occurring signalling protein that is thought to activate the body’s tissue repair pathways, using a plasmid vector. The agreement grants Astellas a licence to develop JVS-100 through phase 2a clinical studies, with an option to acquire the therapy for further development and commercialisation if all goes according to plan. Juventas has already tested the candidate in early-stage trials involving more than 180 patients in other indications, including repeat administrations, and says it has no significant side effects. Read more.
Source: PMLiVE, November 23, 2018
SOME men with prostate cancer are willing to accept lower survival odds to avoid incontinence, impotence and repeat treatments, according to researchers. Prostate cancer is one of the most common forms of cancer in men but in many cases it is a slow growing disease with relatively good survival, even if left untreated. Treatment can include surgery or radiotherapy, but both can cause urinary incontinence and a loss of sexual function. Some patients will spend weeks or months recovering from treatments and some may need a second round of treatment. A new British study suggests that while patients value a longer life, they also value quality of life and may be willing to choose less treatment on that basis. Read more.
Source: The Senior, November 13, 2018